USCAP 2022 Modern Approaches to Classification of Hematolymphoid Neoplasms 2022

Overview

USCAP 2022 Modern Approaches to Classification of Hematolymphoid Neoplasms 2022 provides comprehensive on-demand educational content focused on the classification and diagnosis of hematolymphoid neoplasms. This course includes detailed video presentations and supporting PDFs that facilitate enhanced understanding of complex hematopathology topics.

On-demand hematopathology education — accessible anytime, anywhere.

Format: 8 videos and 8 PDFs
Total size: 16 GB

Agenda

This series of presentations covers key diagnostic and prognostic aspects relevant to hematolymphoid neoplasms, delivered by experts in the field.

• Myelodysplastic Syndrome and Its Differential Diagnosis — Kaaren K. Reichard, MD
• Myeloproliferative Neoplasms and Progression in Myeloid Neoplasms — Kaaren K. Reichard, MD
• Cutaneous Lymphomas and Atypical Cutaneous Lymphoid Proliferations — Elaine S. Jaffe, MD
• Very Abnormal Lymph Nodes — Elaine S. Jaffe, MD
• Uncommon Patterns of Common Lymphomas — Yuri Fedoriw, MD
• When the Malignant Cells are in the Minority (Hodgkin and Hodgkin Mimics) — Yuri Fedoriw, MD
• Prognostic and Predictive Biomarkers — Olga K. Weinberg, MD
• Circulating Neoplasms — Olga K. Weinberg, MD

Speakers

• Kaaren K. Reichard, MD
• Elaine S. Jaffe, MD
• Yuri Fedoriw, MD
• Olga K. Weinberg, MD

Target Audience

This course is designed specifically for training and practicing pathologists seeking to strengthen their expertise in hematolymphoid neoplasm classification and diagnosis.

Why This Topic Matters

USCAP 2022 Modern Approaches to Classification of Hematolymphoid Neoplasms 2022 addresses critical advances in the pathology of hematolymphoid cancers, offering pathologists essential insights into accurate diagnosis and subclassification. These insights support informed clinical decision-making in the complex hematopathology specialty.

MedHub Central provides this focused educational resource to support practitioners aiming to enhance their diagnostic confidence and knowledge in hematolymphoid neoplasms, a field requiring continuous learning due to evolving classification standards and biomarker developments.